The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma
NCT06553040 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87
Last updated 2024-08-14
Summary
The aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (HALP score) and lymphocyte-C-reactive protein ratio (LCR) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma.
Conditions
- Pancreatic Neoplasms
- Pancreas Cancer
Sponsors & Collaborators
-
Ege University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2021-12-01
- Completion
- 2023-01-01
More Related Trials
-
A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer
NCT04024358 ·Status: ACTIVE_NOT_RECRUITING
-
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
NCT05547074 ·Status: COMPLETED
-
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
NCT01692873 ·Status: COMPLETED ·Phase: NA
-
HER-2 Expression in Pancreatic Duct Adenocarcinoma
NCT06055647 ·Status: COMPLETED
-
New Predictive Marker for Pancreatic Cancer Using CA19-9 and Fecal Elastase
NCT05923567 ·Status: ACTIVE_NOT_RECRUITING
-
SII And PALBI is Associated With the Prognosis of Pancreatic Cancer Surgery(SII,PALBI)
NCT05012540 ·Status: COMPLETED
-
Early Recurrence After Surgery for Pancreatic Cancer
NCT07241676 ·Status: ENROLLING_BY_INVITATION
-
Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma
NCT05248750 ·Status: RECRUITING
-
Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice
NCT02277834 ·Status: COMPLETED
-
A Predictive Model for Recurrent Acute Pancreatitis
NCT06464887 ·Status: COMPLETED
-
Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer
NCT06747481 ·Status: RECRUITING
-
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
NCT03334708 ·Status: RECRUITING
-
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT06151223 ·Status: RECRUITING
-
RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer
NCT04575363 ·Status: RECRUITING ·Phase: NA
-
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616 ·Status: TERMINATED ·Phase: NA
-
Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
NCT05483257 ·Status: COMPLETED
-
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer
NCT04560270 ·Status: COMPLETED ·Phase: NA
-
Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
NCT03536793 ·Status: RECRUITING
-
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma
NCT01219829 ·Status: COMPLETED
-
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347 ·Status: WITHDRAWN
-
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
NCT04835064 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma
NCT05228808 ·Status: UNKNOWN
-
Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
NCT02817308 ·Status: UNKNOWN ·Phase: NA
-
Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients
NCT02456051 ·Status: TERMINATED
-
Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer
NCT06515587 ·Status: RECRUITING ·Phase: NA